Canagliflozin boosts A1C, beta-cell function in type 2 diabetes

05/6/2013 | Healio

Type 2 diabetes patients who used canagliflozin as an add-on to metformin/sulfonylurea treatment showed better A1C rates at 26 weeks compared with those in the placebo group, a study indicated. Researchers also noted improvements in insulin secretion rates and beta-cell function among canagliflozin-treated patients. The findings were presented at the American Association of Clinical Endocrinologists annual meeting.

View Full Article in:

Healio

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC